| Description |
NLRP3-IN-15 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-15 inhibits IL-1β release with an IC50 of 0.114 μM. NLRP3-IN-15 can be used for the research of inflammation[1].
|
| Related Catalog |
|
| Target |
NLRP3 inflammasome
|
| In Vitro |
NLRP3-IN-15 (化合物 12a) 抑制 IL-1β 释放，IC50 为 0.114 μM (ELISA 测定) [1]。 NLRP3-IN-15 (2 μM，3 小时) 抑制小鼠腹膜巨噬细胞 (PM) 中 IL-1β (p17) 和 caspase-1 (p20) 的分泌[1]。 NLRP3-IN-15 通过抑制 ASC 寡聚化来抑制 NLRP3 炎性体复合物的形成[1]。 NLRP3-IN-15 在人和小鼠肝微粒体中表现出代谢稳定性 (T1/2: 693 min; Clint: 2.0 μL/min/mg)[1]. Western Blot Analysis[1] Cell Line: Mice peritoneal macrophages(PMs) Concentration: 2 μM Incubation Time: 3 h Result: Inhibited the secretion of IL-1β (p17) and caspase-1 (p20), without affecting pro-IL-1β and pro-caspase-1.
|
| In Vivo |
NLRP3-IN-15 (化合物 5j) (50 mg/kg;i.p.) 在败血症小鼠模型中表现出抗炎作用[1]。 Animal Model: LPS-induced inflammatory septic mouse model[1] Dosage: 50 mg/kg Administration: i.p. Result: Decreased the release of IL-1β in mouse serum. Relieved thickening of the alveolar wall in lung. Animal Model: Mice[1] Dosage: 20 mg/kg Administration: p.o. or i.p. Result: Pharmacokinetic profile of NLRP3-IN-15 (compound 12a). parameter dose (mg/kg) T1/2 (h) Tmax (h) F (%) PO 20 1.659 0.5 9.6 IP 20 1.807 0.167 21.2
|
| References |
[1]. Li J, et al. Scaffold Hybrid of the Natural Product Tanshinone I with Piperidine for the Discovery of a Potent NLRP3 Inflammasome Inhibitor. J Med Chem. 2023 Feb 23;66(4):2946-2963.
|
